Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

PartnershipocrelizumabPositive

AI Analysis

Summary

Teva and Polpharma Biologics announced a global licensing agreement for a biosimilar candidate to Ocrevus (ocrelizumab) for multiple sclerosis treatment.

Outcome Details

Global licensing agreement for biosimilar candidate

Importance:6/10

Sentiment:

0.50

licensingbiosimilarmultiple sclerosispartnership

Related Companies

$TEVA

Read the original article

Published by yahoo_finance on July 9, 2026 12:45 PM

Read Original